ArticleVaccine2020
HPV vaccine coverage and acceptability among a national sample of sexual minority women ages 18-45.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Clinicians' self-reported HPV vaccination recommendations for sexual and gender minority patients.Vaccine · 2026Article
- Health Outcome Determinants of Human Papillomavirus Vaccination in Adult Women in Spain.Vaccines · 2026Article
- Improving HPV Vaccine Coverage in Tennessee: Addressing Barriers and Expanding Access for Mid-Adults.Pathogens (Basel, Switzerland) · 2025Review
- Identifying the Gaps in Human Papillomavirus (HPV) Vaccine Uptake: An Exploratory Factor Analysis of Adults in Tennessee.Vaccines · 2024Article
- HPV vaccine behaviors and intentions among a diverse sample of women aged 27-45 years: implications for shared clinical decision-making.BMC public health · 2024Article
- Older adults' acceptance of the COVID-19 vaccine: Application of the health belief model.Nursing open · 2023Article
- Perspectives Associated with Human Papillomavirus Vaccination in Adults: A Qualitative Study.Vaccines · 2023Article
- Article
- Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review.Open forum infectious diseases · 2023Review
- Facilitators and Barriers of HPV Vaccine Acceptance, Initiation, and Completion among LGBTQ Community in the U.S.: A Systematic Review.International journal of sexual health : official journal of the World Association for Sexual Health · 2022Article
- Improving the Acceptability of Human Papillomavirus Vaccines Among Men Who Have Sex With Men According to the Associated Factors: A Systematic Review and Meta-analysis.Frontiers in pharmacology · 2021Article
- Social capital interventions for human papillomavirus (HPV) immunization and cervical cancer screening: A rapid review.Canada communicable disease report = Releve des maladies transmissibles au CanadaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSexual minority women (lesbian, bisexual, and other women who have sex with women) are at risk for human papillomavirus (HPV) infection and HPV-related disease, demonstrating the importance of HPV vaccination for these women.
methodsWe conducted an online survey of sexual minority women ages 18-45 from the United States (n = 505) in October 2019, about two months after HPV vaccine recommendations were expanded to include ages 27-45. Multivariable Poisson regression identified correlates of HPV vaccine initiation (i.e., receipt of at least one HPV vaccine dose).
resultsOverall, 65% of participants ages 18-26 and 33% of participants ages 27-45 had initiated the HPV vaccine series. Among participants ages 18-26, initiation was more common among those who had received a healthcare provider recommendation (RR = 2.19, 95% CI: 1.64-2.93) or had disclosed their sexual orientation to their primary healthcare provider (RR = 1.33, 95% CI: 1.07-1.65). Among initiators ages 27-45, a large majority (89%) reported receiving their first dose before turning age 27. Initiation was more common among participants ages 27-45 who had received a healthcare provider recommendation (RR = 3.23, 95% CI: 2.31-4.53) or who reported greater perceived social support for HPV vaccination (RR = 1.22, 95% CI: 1.05-1.40). Several reasons for not yet getting HPV vaccine differed by age group (ages 18-26 vs. ages 27-45; all p < 0.05).
conclusionsMany sexual minority women, particularly those ages 27-45, remain unvaccinated against HPV. Findings provide early insight into HPV vaccine coverage among adult women and highlight key leverage points for increasing vaccination among this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.